±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 5275  |  »Ø¸´: 10

lidong.0107

Í­³æ (СÓÐÃûÆø)


[½»Á÷] cancer research Ͷ¸åÒªÇó

ÏëÇë½Ìһϣ¬cancer  researchµÄͶ¸åÓÐʲôҪÇóÂð£¿ÎÄÕ¸ñʽÓÐʲôҪÇóÂð£¿
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
»ØÌûÖ§³Ö ( ÏÔʾ֧³Ö¶È×î¸ßµÄǰ 50 Ãû )
¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
¿´Ìì: ½ð±Ò+2, ¹ÄÀøÒ»Ï 2012-11-20 21:10:49
2Â¥2012-11-16 17:39:30
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
ÆÕͨ»ØÌû

ÉúÎïСͨ

ľ³æ (ÕýʽдÊÖ)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Â¥Ö÷ÊÇÄĵģ¿ÕâôÉñÓ£¡
3Â¥2012-11-16 20:37:01
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

DougSong

ľ³æ (ÖøÃûдÊÖ)


Ͷ¸å¾ÍÒª75µ¶¡£¡£¡£¡£
4Â¥2012-11-19 04:22:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lidong.0107

Í­³æ (СÓÐÃûÆø)


ÒýÓûØÌû:
4Â¥: Originally posted by DougSong at 2012-11-19 04:22:18
Ͷ¸å¾ÍÒª75µ¶¡£¡£¡£¡£

ʲôÒâ˼£¿
5Â¥2012-11-20 13:40:02
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

DougSong

ľ³æ (ÖøÃûдÊÖ)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Ͷ¸åµÄʱºò¾ÍÐèÒª½»submission·Ñ75ÃÀÔª

[ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]
6Â¥2012-11-20 18:49:42
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lidong.0107

Í­³æ (СÓÐÃûÆø)


»¹ÏëÇë½Ìһϣ¬ÎÄÏ×ÊǶ¼±ØÐë²åÔÚÿ¾ä»°µÄ×îºóÂ𣿻¹ÊÇÄÄÀï¶¼¿ÉÒÔ²åÄØ£¿
7Â¥2012-11-21 10:46:04
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

y_bing41

гæ (ÕýʽдÊÖ)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÒýÓûØÌû:
6Â¥: Originally posted by DougSong at 2012-11-20 18:49:42
Ͷ¸åµÄʱºò¾ÍÐèÒª½»submission·Ñ75ÃÀÔª

Â¥Ö÷´íÁË£¬Ã»ÓÐÒªÇó½»Ç®°¡£¬ÎÒÃÇͶµÄÂÛÎÄûÓÐÒªÇó½»Ç®Ä¿Ç°ÒѾ­ËÍÉó¡£
8Â¥2014-02-03 23:51:23
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

y_bing41

гæ (ÕýʽдÊÖ)


½¨ÒéÕÒһƪ×î½üµÄÂÛÎÄ·ÂÕÕ¸ñʽ¸Äһϣ¬ÎÒÃǾÍÊÇÕâô¸ãµÄ£¬Ã»É¶´óÎÊÌ⣬ĿǰÒѾ­ËÍÉó£¬Ò²Ã»ËµÒª½»Éó¸å·Ñ¡£
9Â¥2014-02-03 23:52:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

DougSong

ľ³æ (ÖøÃûдÊÖ)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Cancer Research (CanRes):
Instructions for Authors


SmartSubmit

Scope
Cancer Research is the most frequently cited cancer journal in the world. The journal publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience spanning basic, preclinical, clinical, prevention, and epidemiologic research. Cancer Research seeks manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and societal problems posed by cancer. The main scope of the journal is captured in its primary subsections, which focus on molecular and cellular pathobiology, tumor and stem cell biology, therapeutics and targets, microenvironment and immunology, prevention and epidemiology, and integrated systems and technology. Please note that the journal is unable to entertain pre-submission inquiries. See the Submission Procedures section of the Instructions for Authors for information on submitting a manuscript for consideration.

Papers are stringently reviewed, and only those that report results of novel, timely, and broadly-significant research meeting high standards of scientific merit are accepted for publication. The following criteria provide an overview of the types of studies considered by the journal:

Findings which have not been previously published in another tumor model.
Studies performed in multiple cell lines.
Conclusions which are not representative of incremental findings.
Studies which include a clearly written title and abstract which communicate the study's impact of significance to non-experts.
An incisive rationale that could interest a broad audience.
Manuscripts containing in vivo data. Although in vivo data is not required, studies containing this data are preferred.
A potentially generalizable, broad impact conclusion.
Studies which describe RNA interference (RNAi) must contain one non-specific control and two specific siRNAs for each knockdown target of interest. Additional data showing that knockdown at the level of protein expression (not just mRNA) was achieved is required.
Categories of Publication        Top
The following types of articles will be considered for publication. Note that word counts are exclusive of references. Authors are advised that submissions not adhering to the guidelines provided below, including word counts, may be returned unreviewed.

Research Articles       
Original studies offering broad impact across the fields of basic, preclinical, clinical, prevention and epidemiologic cancer research. The reports should be well-documented, novel, and significant to the field as a whole. The Editor-in-Chief and members of the senior editorial board reserve the right to edit title, abstract, and pr¨¦cis for articles that are accepted to improve their clarity, brevity, and quality.

250-word abstract
5,000 words of text
7 tables and/or figures (Please keep the number of panels per figure to an absolute minimum)
50 references

Priority Reports       
Short, definitive reports of findings of high impact, significance, and timeliness. These reports receive an accelerated review. Papers submitted as Priority Reports should include a section for Materials and Methods as well as Results and Discussion (Results and Discussion may be combined but Materials and Methods may not be combined with any other section). The Editor-in-Chief and members of the senior editorial board reserve the right to edit title, abstract, and pr¨¦cis for articles that are accepted, to improve their clarity, brevity, and quality.

250-word abstract
2,500 words of text
4 tables and/or figures ¡ª Please note that each figure or table is limited to a maximum of 4 panels.
20 references

Reviews       
Articles that review a timely subject important to cancer researchers. Reviews must be written as concisely as possible. Authors of unsolicited Review Articles must first submit an outline of the proposed article for consideration. The outline should be sent to the attention of Dr. Danny R. Welch, Deputy Editor for Reviews (Fax: (215) 440-9354; E-mail: cancerres@aacr.org). All Review Articles, whether invited or not, will be subject to peer review. The length restrictions for this category of publication are provided below. Longer reviews will be considered only at the discretion of the Deputy Editor for Reviews.

200-word abstract
2,000 words of text
1 original figure with a maximum of 4 panels
30 references

Perspectives in Cancer Research       
Articles that present fresh insights on a very active or underdeveloped area of research, with a personal viewpoint on the area, its pressing issues, or its development.

200-word abstract
3,000 words of text
3 tables and/or figures, each with a maximum of 4 panels
30 references

Public Issues       
Brief articles on topics of interest to cancer researchers and the general public. These topics might include articles on advocacy for funding cancer research, government relations, training in the field, public education, or science education.

2,000 words of text

Letters to the Editor       
In the spirit of open scientific dialogue, the Editors invite the submission of correspondence that presents considered opinions in response to articles published in the journal. Letters to the Editor will be peer reviewed and, if found to meet the requisite publication criteria (scholarly commentary on a subject of importance and interest to the broad readership), the Letter may be sent to the author(s) of the originally published article and possibly to other interested parties for a response to be published in the same issue of the journal as the Letter. Please note that the journal will not consider Letters to the Editor regarding Cancer Research articles that were published more than 3 months prior. Correspondence concerning articles that have not been published in Cancer Research will not be considered. The length restrictions for this category of publication are as follows:

400 words of text
5 references, the first of which must be the citation for the original article under discussion
Letters may contain figures or tables only if they show data that refute the conclusions of the originating article. Figures or tables showing unpublished data in support of the conclusions of the originating article will not be considered.
Include a title: "Running title of the original article" ¡ª Letter

Meeting Reports       
Brief reports of symposia and conferences in cancer research. Reports must be submitted within 2 months of the meeting date in order to maintain their timeliness. Only those Meeting Reports dealing with topics of interest to the readership that contain novel information and insights from the meeting will be accepted for publication. A Meeting Report should offer a thoughtful, critical commentary that shows an appreciation of the connections among various presentations and reveals the consensus, if any, that emerged on matters of importance at the meeting. Before submitting a Meeting Report for consideration, potential authors must send a letter to the attention of Dr. Mariano Barbacid, Deputy Editor for Meeting Reports, to inquire whether the suggested meeting satisfies criteria for consideration. Letters of inquiry should be sent to the Publications Office (Fax: (215) 440-9354; E-mail: cancerres@aacr.org). Length restrictions for this category of publication are as follows:

100 word abstract
2,500 words of text
Figures and/or tables are not permitted without prior approval from the Editors
References, if necessary, must be kept to a minimum
A statement of the purpose of the meeting, an integrated summary of the findings presented, and recommendations for future research
The names and affiliations of key speakers should be given in an appendix that is submitted as supplemental information, not as part of the manuscript text

Mathematical Oncology Research Articles       
Published in the Integrated Systems and Technologies section of the journal, Mathematical Oncology articles include mathematical approaches to problems in cancer research. These articles will contain new testable hypotheses, integration of theory and experimental data, facilitation of wide-ranging investigations, and basic laws of biology. The format and length restrictions for this category of publication are as follows:

Title: 150 characters (not including spaces)

Abstract: 350 words, in the following construction:

Summarize the background, cancer significance, and question "set the stage"
Describe the findings ("deliver the result"
Summarize the meaning and implication of the advance ("place in context"
Succinct nonmathematical description of the major results; please use the subheading Major Findings to differentiate this portion of the abstract
Quick Guide to Equations and Assumptions: Up to 5 equations, 800 words maximum

Present key equations; for each, include a description and/or definition of the components of the equation
Present all major assumptions of the model
Body Text: 5,000 text words

Figures and/or Tables: maximum of 7. Authors are asked to keep the number of panels per figure to an absolute minimum.

Acceptable formats: TIFF, EPS, PPT
Submit figures and tables as separate files
References: 50

Supplementary Material: Submit the details of the computational procedures and a flowchart of the algorithm(s) as Supplementary Material. Cancer Research encourages that all programs used in the calculations or detailed instructions to replicate the major findings also be provided as Supplementary Material. Prior to depositing a program, you must ensure and attest that the posted version executes properly.

Deposit data used for analysis (curve fitting, approximations, parameter estimation, etc.) as Supplementary Material.
10Â¥2014-02-04 03:03:16
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yxw14612

гæ (³õÈëÎÄ̳)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÒýÓûØÌû:
4Â¥: Originally posted by DougSong at 2012-11-19 04:22:18
Ͷ¸å¾ÍÒª75µ¶¡£¡£¡£¡£

ÄúºÃ£¬ÇëÎÊÄÄÀïдµÄÒª½»75ÃÀÔª£¿ÎÒÔÚinstructionÀïÕÒÁ˰ëÌìҲûÕÒµ½£¬Ö»ÓÐpage fee£¬ÊÇʲôʱºòÒª½»ÄØ£¿£¿
11Â¥2014-08-12 17:11:11
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ lidong.0107 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 304Çóµ÷¼Á +5 c297914 2026-04-05 5/250 2026-04-05 19:05 by ms629
[¿¼ÑÐ] Ò»Ö¾Ô¸9²ÄÁÏѧ˶297ÒѹýÁù¼¶Çóµ÷¼ÁÍÆ¼ö +11 adaie 2026-04-04 12/600 2026-04-05 19:04 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 22408 ×Ü·Ö320£¬Ò»ÆªÂÛÎĶþ×÷£¬Á½¸ö¹úÈý£¬Çóµ÷¼Á +3 Leomulufu 2026-04-04 5/250 2026-04-05 19:04 by chongya
[¿¼ÑÐ] µ÷¼Á +4 ²»·ê´º 2026-04-05 4/200 2026-04-05 18:07 by ms629
[¿¼ÑÐ] Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶ +10 @taotao 2026-03-30 10/500 2026-04-05 17:57 by jj987
[¿¼ÑÐ] 282Çóµ÷¼Á +3 aaa³µÁ¾ 2026-04-01 3/150 2026-04-05 17:03 by yulian1987
[¿¼ÑÐ] 298·Ö 070300Çóµ÷¼Á +15 zwen03 2026-04-02 15/750 2026-04-05 12:52 by Hdyxbekcb
[¿¼ÑÐ] µç×ÓÐÅÏ¢µ÷¼Á½»²æÑ§¿ÆÓÐÍÆ¼öÂð +6 jhtfeybgj 2026-04-01 9/450 2026-04-05 11:13 by Öí»á·É
[¿¼ÑÐ] 266·Ö£¬Ò»Ö¾Ô¸µçÆø¹¤³Ì£¬±¾¿Æ²ÄÁÏ£¬Çó²ÄÁÏרҵµ÷¼Á +11 ÍÛºôºßºôºß 2026-04-01 12/600 2026-04-04 23:17 by ÓÀ×ÖºÅ
[¿¼ÑÐ] ÇóÉúÎïѧµ÷¼Á +14 15172915737 2026-04-01 14/700 2026-04-04 20:13 by babysonlkd
[¿¼ÑÐ] 291Çóµ÷¼Á +4 ÃÔÃÉľľ 2026-04-01 5/250 2026-04-04 15:59 by sihailian3
[¿¼ÑÐ] »¯¹¤Çóµ÷¼Á +11 ÀóÏã֥ʿҬÄÌ 2026-04-03 11/550 2026-04-03 22:06 by à£à£à£0119
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖÐũҵ071010£¬×Ü·Ö320Çóµ÷¼Á +7 À§À§À§À§À¤À¤ 2026-04-02 7/350 2026-04-03 17:26 by Yuena_Wang
[¿¼ÑÐ] 320Çóµ÷¼Á +3 ũҵ¹¤³ÌÓëÐÅÏ¢¼ 2026-04-03 3/150 2026-04-03 11:40 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] 316Çóµ÷¼Á +14 ÖÛ×Ô¹£ 2026-04-01 18/900 2026-04-03 10:28 by linyelide
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +6 ´Þwj 2026-04-02 6/300 2026-04-03 10:19 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 372·Ö²ÄÁÏÓ뻯¹¤£¨085600£©Ò»Ö¾Ô¸ºþÄÏ´óѧÇóµ÷¼Á +5 À¶¼ãƬ 2026-04-02 6/300 2026-04-02 21:37 by dongzh2009
[¿¼ÑÐ] һ־Ըɽ¶«´óѧ£¬085600£¬344 +7 κ×Óper 2026-04-02 8/400 2026-04-02 21:12 by °ÙÁéͯ888
[¿¼ÑÐ] 07ÉúÎïѧÇóµ÷¼Á һ־Ըͬ¼Ã´óѧ359·Ö +3 LAMC. 2026-03-30 3/150 2026-04-02 10:26 by 18828373951
[¿¼ÑÐ] 085602»¯Ñ§¹¤³Ì268·Ö¶×µ÷¼Á +8 ÔÂÕÕ»¨ÁÖ¡£ 2026-04-01 8/400 2026-04-01 22:08 by Î޼ʵIJÝÔ­
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û